ProMACE-MOPP regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
ProMACE-MOPP regimen refers to a regimen consisting of prolix (prednisone), methotrexate, adriamycin (doxorubicin), cyclophosphamide, etoposide, mustargen (mechlorethamine), oncovin (vincristine), procarbazine, prednisone used to treat diffuse large B-cell lymphoma[1] and primary CNS lymphoma.[2]
Regimen
ProPrednisone
MMethotrexate
AAdriamycin (Doxorubicin)
CCyclophosphamide
EEtoposide
MMustargen (Mechlorethamine)
OOncovin (Vincristine)
PProcarbazine
PPrednisone
Indications
References
- ↑ 1.0 1.1 Sertoli MR, Santini G, Chisesi T, Congiu AM, Rubagotti A, Contu A; et al. (1994). “MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin’s lymphoma: results of a prospective randomized trial by the non-Hodgkin’s Lymphoma Cooperative Study Group”. J Clin Oncol. 12 (7): 1366–74. PMID 7517442.
- ↑ 2.0 2.1 Yamanaka R, Morii K, Shinbo Y, Takeuchi S, Tamura T, Hondoh H; et al. (2005). “Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma”. Ann Hematol. 84 (7): 447–55. doi:10.1007/s00277-005-1005-9. PMID 15747120.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH